The
global Urinary
Tract Infection Testing Market is expected to reach USD 765.6 million
by 2030, according to a new report by Grand View Research, Inc. The UTI testing
market is witnessing growth due to factors such as rising disease burden,
increasing geriatric population, rapid technological advancements, and high
R&D investments by key players to introduce novel & innovative
products, such as self-testing & rapid Point-of-Care (PoC) devices
products.
Urinary
tract infection is becoming a common global concern. According to research
studies, UTI occurs in one in five adult women at some point in their life. In
the U.S., about 25%-40% of women aged 20-40 have suffered a UTI. In the U.S.,
about 250,000 cases of pyelonephritis are reported every year. In women aged
18-19, its incidence is about 28/10,000, out of which 7% of cases require
hospital admission. Genetic and cultural factors may influence its prevalence;
for instance, in South Korea, the incidence of pyelonephritis is around
59/10,000. Its recurrence is more common than other UTIs, with the recurrence
rate being 5.7% in men and 9% in women.
Patients
with diabetes are at increased risk of developing urinary tract infections such
as acute cystitis, and therefore, the increasing global prevalence of diabetes
is likely to contribute to cystitis growth. According to an NCBI article, type
2 diabetes raises UTI risk and patients with type 2 diabetes experience
frequent & severe UTIs. According to the International Diabetes Federation
(IDF) data from 2021, approximately 643 million individuals will have diabetes
by 2030 and 783 million by 2045. Moreover, the estimated prevalence of
asymptomatic bacteriuria in diabetic females is 26%, compared to 6% in
nondiabetic females. Such factors are expected to boost the prevalence of
cystitis globally.
However,
due to the rise in awareness about such diseases, the demand for specialist
treatment has increased in recent years. According to the U.S. Department of
Health and Human Services, in the U.S., the number of practicing urologists in
2020 was 4.07 per 100,000 populations. The report further stated that due to
the rise in demand, a shortage of urologists was observed, which is likely to
exceed nearly 3,600 physicians by 2025. This can impede market growth in the
coming years. Moreover, COVID-19 has had a detrimental impact on the industry.
Individuals with UTIs have experienced substantial disruptions in testing and
emergency care.
Key
players are introducing novel products to strengthen their portfolios. For
instance, in September 2021, OpGen, Inc. announced initiating clinical trials
of the Unyvero Urinary Tract Infection Panel. The panel can analyze a broad
range of pathogens and antimicrobial resistance markers directly from a urine
sample. Successful clinical trials and the launch of such technologically
advanced & efficient products are anticipated to drive market growth over
the coming years. Similarly, in July 2020, Uqora, Inc. (Pharmavite, LLC), a
urinary health biotechnology company, launched a UTI diagnostic and management
kit. The kit includes a rapid UTI diagnostic device, Clarify, compatible with a
PoC and homecare setting.
Related Press
Release@ Urinary
Tract Infection Testing Market Report
Urinary Tract Infection Testing Market Highlights
- Cystitis
dominated the market in 2021, with an estimated market share of 41.56%.
This can be attributed to the high incidence & recurrence rate of
cystitis, increased number of product approvals, and the high number of
diabetes patients who are more prone to cystitis
- The general
practitioner segment held a share of 12.41% in 2021. It is the primary
point of contact for most patients with UTI, and in most cases,
uncomplicated UTI is diagnosed and treated by a general practitioner
- North
America dominated the overall urinary tract infection market in terms of
value. This can be attributed to better reimbursement facilities and a
rise in the adoption of novel diagnostic products due to increased
awareness
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment